Lupus & antiphospholipid syndrome
Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry
Authors' conclusion
At week 26 after initiating anifrolumab therapy, ∼90% of patients remained on therapy.
Study context
- Population
- Systemic lupus erythematosus (SLE) patients who started anifrolumab in real-world clinical practice45 analysed (followed ≥12 weeks)
- Exposure
- Anifrolumab vs standard of care (SoC)
- Outcome
- Retention rate of anifrolumab
- Follow-up
- 26 weeks
Methodological detailsretrospective observational, PS-IPTW adjusted comparison, real-world registry (LOOPS)
- Retrospective observational
- PS-IPTW adjusted comparison
- Real-world registry (LOOPS)
Main finding
As reported in the abstract
week 26
Retention rate
89.7%
Observational data: associations, not effects.
Further findings
| Outcome | Non-LLDAS achievement | Minor flare |
|---|---|---|
| LLDAS achievement rate · up to week 12 | 42.9% | 66.7% |
Lupus Low Disease Activity State (LLDAS) achievement rate · up to week 12
- GC doses and SELENA-SLEDAI score significantly decreased in both groups
Anifrolumab (minor flare) vs SoC or GC dose increase · up to week 12
- GC dose and SLEDAI score significantly lower with anifrolumab than either other group
- No significant difference in LLDAS achievement
- PS-IPTW adjusted
Original publication
Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry. Rheumatology (Oxford). Published 2 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →